Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

HEALWELL to acquire AI firm to help solve data challenges

Jonathon Brown Jonathon Brown, The Market Online
0 Comments| November 15, 2023

{{labelSign}}  Favorites
{{errorMessage}}

  • HEALWELL AI Inc. (TSX:AIDX) has signed an agreement to acquire a majority ownership position in Pentavere Research Group Inc.
  • Pentavere is an AI health-tech company based in Toronto that focuses on identifying eligible patients for approved medications and interventions
  • HEALWELL’s proposed majority acquisition of Pentavere is expected to add revenue, new products, partnerships with major hospital networks in Canada and the United States, access to five new key pharma customers, and an expert AI engineering team
  • HEALWELL AI Inc. last traded at $0.82 per share

HEALWELL AI Inc. (TSX:AIDX) has signed an agreement to acquire a majority ownership position in Pentavere Research Group Inc.

Formerly MCI Onehealth Technologies Inc., HEALWELL is engaged in AI-enabled disease diagnosis to power its solutions in Canada and the United States.

Pentavere is an AI health-tech company based in Toronto that focuses on identifying eligible patients for approved medications and interventions.

HEALWELL’s proposed majority acquisition of Pentavere is expected to add revenue, new products, partnerships with major hospital networks in Canada and the United States, access to five new key pharma customers, and an expert AI engineering team.

This proposed acquisition aligns with HEALWELL’s technological and commercial competencies. The addition of Pentavere’s data abstraction and structuring capabilities, combined with access to hospitals and expertise in hospital-based medical specialties, is expected to significantly broaden HEALWELL’s therapeutic and disease indication spectrum.

“This proposed acquisition will represent a major leap forward in our mission to revolutionize healthcare through the use of AI and data science,” Dr. Alexander Dobranowski, CEO of HEALWELL commented “Pentavere is most certainly one of the leading technology assets in Healthcare AI in Canada. Its advanced DARWEN platform leverages artificial intelligence and large language models to process complex, unstructured clinical data into easily searchable and referenceable structured data, addressing a critical need in modern healthcare technology. Pentavere has established vital partnerships and secured data-access agreements with major hospital networks in Canada and the United States, solidifying its position as a leader in the industry.”

According to whitepaper, “The Digitization of the World – From Edge to Core”, by the year 2025, the compound annual growth rate of data for healthcare will reach 36 per cent). Much of this data is generated in unstructured form and will require technologies such as Pentavere’s to structure such that it can be used to solve the most challenging problems in the healthcare industry.

HEALWELL AI Inc. is a healthcare technology and data science company focused on preventative care, with a vision to improve healthcare and save lives through early identification and detection of disease. The company leverages AI for patients and doctors to deliver increased access, reduce healthcare costs, and improve patient outcomes.

HEALWELL AI Inc. last traded at $0.82 per share.

Join the discussion: Find out what everybody’s saying about this stock on the HEALWELL Bullboard, and check out the rest of Stockhouse’s stock forums and message boards.

The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.



Tags:

{{labelSign}}  Favorites
{{errorMessage}}